Mizuho Securities Downgrades DepoMed Inc (DEPO) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Depomed (DEPO): Raising PT 30% But Keeping Neutral Rating - UBS
October 3, 2016 8:06 AM EDTUBS analyst, Ami Fadia, reiterated her Neutral rating on shares of DepoMed Inc (NASDAQ: DEPO) but raised her price target to $26.00 from $20.00 after the the District Court of New Jersey upheld the validity of all three of the Nucynta litigated patents.... More
Janney Montgomery Scott Reiterates Buy as Court Rules in Favor of Depomed (DEPO)
October 3, 2016 7:55 AM EDTJanney Montgomery Scott reiterated a Buy rating on DepoMed Inc (NASDAQ: DEPO), and raised the price target to $31.00 (from $28.00), following a court ruling in favor of the company. The Court issued an Order in favor of DEPO in its patent litigation against and secures Nucynta through... More
Depomed (DEPO): Favorable Court Ruling, Mostly Expected - Mizuho
October 3, 2016 6:47 AM EDTMizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of DepoMed Inc (NASDAQ: DEPO) after the District Court ruled in favor of the company on the '364 and '593 patents which will prevent generic entry prior to patent expiry in December... More
Depomed (DEPO) to Resume Trading at 4;20 PM ET
September 30, 2016 4:07 PM EDTDepomed (NASDAQ: DEPO) to Resume Trading at 4;20 PM ET
... MoreDepomed (DEPO) Announces Favorable Ruling on NUCYNTA Providing Market Exclusivity Until December 2025
September 30, 2016 3:56 PM EDTDepomed, Inc. (Nasdaq: DEPO) today announced that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation against all three filers of Abbreviated New Drug Applications (ANDAs) for Depomed's NUCYNTA franchise. With the courts ruling, Depomed expects market... More
Depomed (DEPO) Wins Order Obtaining Injunction vs. Defendants Over Generic Nucynta (AGN)
September 30, 2016 3:19 PM EDTDepomed (Nasdaq: DEPO) wins order obtaining injunction blocking generic version of Nucynta, according to Bloomberg.
Allergan (NYSE: AGN) can't sell generic Nucynta pending final judgment. Actavis, Roxane also lost an effort to invalidate Nucynta patents.
Depomed's patents on Nucynta expire between 2022 and 2028.
... More
